HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

被引：188

作者：

Ortiz, GM ^{[1
]}

Nixon, DF ^{[1
]}

Trkola, A ^{[1
]}

Binley, J ^{[1
]}

Jin, X ^{[1
]}

Bonhoeffer, S ^{[1
]}

Kuebler, PJ ^{[1
]}

Donahoe, SM ^{[1
]}

Demoitie, MA ^{[1
]}

Kakimoto, WM ^{[1
]}

Ketas, T ^{[1
]}

Clas, B ^{[1
]}

Heymann, JJ ^{[1
]}

Zhang, LQ ^{[1
]}

Cao, YZ ^{[1
]}

Hurley, A ^{[1
]}

Moore, JP ^{[1
]}

Ho, DD ^{[1
]}

Markowitz, M ^{[1
]}

机构：

[1] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 1999年 / 104卷 / 06期

关键词：

D O I：

10.1172/JCI7371

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1-infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in I subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1-specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1-specific immune responses should be considered as an adjunctive treatment strategy for HIV-1-infected individuals on HAART.

引用

页码：R13 / R18

页数：6

共 32 条

[1] Antiretroviral therapy in countries with low health expenditure [J].

Arya, SC .

LANCET, 1998, 351 (9113) :1433-1434

[2] Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [J].

Borrow, P ;

Lewicki, H ;

Wei, XP ;

Horwitz, MS ;

Peffer, N ;

Meyers, H ;

Nelson, JA ;

Gairin, JE ;

Hahn, BH ;

Oldstone, MBA ;

Shaw, GM .

NATURE MEDICINE, 1997, 3 (02) :205-211

[3] VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].

BORROW, P ;

LEWICKI, H ;

HAHN, BH ;

SHAW, GM ;

OLDSTONE, MBA .

JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110

[4] RETRACTED: Characterization of long-term survivors of human immunodeficiency virus type 1 infection (Retracted article. See vol 64, U5, 1998) [J].

Cao, YZ ;

Qin, LM ;

Zhang, LQ ;

Safrit, J ;

Ho, DD .

IMMUNOLOGY LETTERS, 1996, 51 (1-2) :7-13

[5] Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J].

Chun, TW ;

Stuyver, L ;

Mizell, SB ;

Ehler, LA ;

Mican, JAM ;

Baseler, M ;

Lloyd, AL ;

Nowak, MA ;

Fauci, AS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13193-13197

[6] Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines [J].

Connor, RI ;

Korber, BTM ;

Graham, BS ;

Hahn, BH ;

Ho, DD ;

Walker, BD ;

Neumann, AU ;

Vermund, SH ;

Mestecky, J ;

Jackson, S ;

Fenamore, E ;

Cao, Y ;

Gao, F ;

Kalams, S ;

Kunstman, KJ ;

McDonald, D ;

McWilliams, N ;

Trkola, A ;

Moore, JP ;

Wolinsky, SM .

JOURNAL OF VIROLOGY, 1998, 72 (02) :1552-1576

[7] Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy [J].

Finzi, D ;

Blankson, J ;

Siliciano, JD ;

Margolick, JB ;

Chadwick, K ;

Pierson, T ;

Smith, K ;

Lisziewicz, J ;

Lori, F ;

Flexner, C ;

Quinn, TC ;

Chaisson, RE ;

Rosenberg, E ;

Walker, B ;

Gange, S ;

Gallant, J ;

Siliciano, RF .

NATURE MEDICINE, 1999, 5 (05) :512-517

[8] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].

Finzi, D ;

Hermankova, M ;

Pierson, T ;

Carruth, LM ;

Buck, C ;

Chaisson, RE ;

Quinn, TC ;

Chadwick, K ;

Margolick, J ;

Brookmeyer, R ;

Gallant, J ;

Markowitz, M ;

Ho, DD ;

Richman, DD ;

Siliciano, RF .

SCIENCE, 1997, 278 (5341) :1295-1300

[9] Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy [J].

Furtado, MR ;

Callaway, DS ;

Phair, JP ;

Kunstman, KJ ;

Stanton, JL ;

Macken, CA ;

Perelson, AS ;

Wolinsky, SM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (21) :1614-1622

[10]

Gray CM, 1999, J IMMUNOL, V162, P1780

← 1 2 3 4 →